CYTO (Altamira Therapeutics Ltd.) Koefisien nilai perusahaan marang pendapatan

Logo perusahaan publik Auris Medical (CYTO)

Altamira Therapeutics (CYTO) has weakened its primary cash flow due to a strategic pivot toward RNA therapy and the divestment of previous assets. Meanwhile, the production of nasal agents and RNA compositions has been delegated to European contractors. The company is expanding its workforce with experts specializing in drug delivery to the brain and ear. The EV/Sales multiple visualizes the debt-free market value, where the metric indicates the status of the current business valuation.

CYTO Rasio nilai perusahaan marang pendapatan Altamira Therapeutics Ltd. (04.07.2022 - 20.11.2026)

CYTO (Altamira Therapeutics Ltd.): rincian analitis lan laporan miturut indikator

- rega saham lan prakiraan rega para ahli:
- indikator valuasi pasar bisnis:
Pambiji fundamental perusahaan:CYTO - Altamira Therapeutics
Produk asli altamiratherapeutics.com

To build a resilient portfolio, I utilize EV/Sales, which compares the total enterprise value of a business to its revenue, eliminating the impact of debt to determine the actual price of one dollar of sales. Amid geopolitical risks hindering the clinical trials of Altamira Therapeutics (CYTO), the EV/Sales multiple trajectory clearly demonstrates the extent to which market expectations are outpacing the company's current operational efficiency.

Pesaing langsung

HLN: Rasio nilai perusahaan marang pendapatan|Kenvue Corp (KVUE) - Rasio nilai perusahaan marang pendapatan|Verona Pharma PLC - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Jyong Biotech Ltd|Multiplikator EV/Sales Ligand Corp|Multiplikator EV/Sales AMRX|Rasio total nilai perusahaan marang pendapatan Perrigo Company plc|Multiplikator EV/Sales ALVO (Alvotech Biopharmaceuticals)|LQDA: Rasio nilai perusahaan marang pendapatan|Galapagos N.V. - Multiplikator EV/Sales|ANIP - Multiplikator EV/Sales|MNKD: Multiplikator EV/Sales|amphastar.com (AMPH) - Multiplikator EV/Sales|PCRX (Pacira Pharmaceuticals) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan ARS Pharmaceuticals, Inc. (SPRY)|Multiplikator EV/Sales TBPH|AQST (Aquestive Therapeutics) - Nilai bisnis marang pendapatan|scPharmaceuticals, Inc. - Nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan TECX|tonixpharma.com - Multiplikator EV/Sales|Nilai bisnis marang pendapatan SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Rasio nilai perusahaan marang pendapatan|Nilai perusahaan marang pendapatan BioHarvest|Nilai perusahaan marang pendapatan EXOZ|Nilai perusahaan marang pendapatan Oramed Pharmaceuticals (ORMP)|Nilai perusahaan marang pendapatan ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Rasio nilai perusahaan marang pendapatan|Multiplikator EV/Sales ABVC (ABVC BioPharma Inc)|CPIX - Nilai perusahaan marang pendapatan|Quantum BioPharma Corp - Multiplikator EV/Sales|FGEN (fibrogen.com) - Rasio nilai perusahaan marang pendapatan|TELO (Telomir Pharmaceuticals) - Nilai perusahaan marang pendapatan|Rani Therapeutics Holdings - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan SNYR|Multiplikator nilai perusahaan marang pendapatan rallybio.com RLYB|Multiplikator EV/Sales LEXX|PULM (Pulmatrix, Inc.) - Nilai bisnis marang pendapatan|Pheton Holdings - Nilai perusahaan marang pendapatan|Multiplikator EV/Sales Aptorum Group Limited APM|LYRA: Nilai perusahaan marang pendapatan|IBO: Rasio nilai perusahaan marang pendapatan|TNFA: Multiplikator EV/Sales|YCBD: Koefisien nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan PainReform Ltd|Rasio nilai perusahaan marang pendapatan LIPO|Rasio nilai perusahaan marang pendapatan optinose.com (OPTN)|PIRS (Pieris Pharma) - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Procaps Group S.A. PROC|Rasio total nilai perusahaan marang pendapatan petrospharma.com (PTPI)|QLI - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Rasio nilai perusahaan marang pendapatan